Becton, Dickinson and Company (NYSE:BDX) announced its earnings results on Wednesday. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the consensus estimate of $2.37 by $0.03, Bloomberg Earnings reports. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. During the same period in the prior year, the firm earned $2.12 EPS. The firm’s revenue for the quarter was down 2.0% on a year-over-year basis.

Several equities research analysts recently weighed in on BDX shares. Cowen and Company reaffirmed an “outperform” rating and set a $230.00 target price (up from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. BidaskClub raised shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price on the stock in a research note on Monday, July 17th. Bank of America Corporation reaffirmed a “buy” rating and set a $225.00 target price (up from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Finally, Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Becton, Dickinson and currently has an average rating of “Buy” and an average target price of $205.79.

In related news, insider Ellen R. Strahlman sold 9,283 shares of Becton, Dickinson and stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the sale, the insider now owns 26,638 shares in the company, valued at $5,279,917.98. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of Becton, Dickinson and stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the sale, the insider now owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. In the last 90 days, insiders sold 75,904 shares of company stock valued at $15,242,688. Insiders own 1.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Becton, Dickinson and Company (BDX) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/02/becton-dickinson-and-company-bdx-issues-quarterly-earnings-results-beats-expectations-by-0-03-eps.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Earnings History for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.